论文部分内容阅读
应用免疫组化SABC法，检测29例D_2期前列腺癌组织中雄激素受体的含量，并观察患者治疗前生活状态、骨转移程度、血浆前列腺特异性抗原、血浆睾酮和血红蛋白浓度等参数与患者预后之间的关系。结果发现：11例雄激素依赖性前列腺癌组中雄激素受体含量、血红蛋白、睾酮浓度分别为（51．0±14．8）％，（119．0±19．0）g/l，（9．8±7．9）ng／ml。而在18例雄激素非依赖性前列腺癌组中则分别为（32．2±118）％，（97．9±18．2）g/l，（4．0±6．4）ng／ml。雄激素受体含量、血红蛋白、睾酮浓度两组相比较，有显著性差异。（2）前列腺特异性抗原、生活状态、骨转移程度在雄激素依赖性前列腺癌组中分别为（122．8±70．5）ng／ml，1．5±0．7，1．4±0．5，在雄激素非依赖性前列腺癌组中则分别为（123．3±52．9）ng／ml，1．8±0.6，1．88±0.7，统计学分析两组没有差异（P＞0．05）。以上结果提示：D_2期前列腺癌组织中雄激素受体含量越高，治疗效果越好。雄激素受体含量的高低是预测晚期前列腺癌患者雄激素阻断治疗效果的良好指标。
The immunohistochemical SABC method was used to detect the levels of androgen receptor in 29 cases of stage D_2 prostate cancer. The patients’ life status, degree of bone metastasis, serum PSA, plasma testosterone and hemoglobin before treatment were observed. The relationship between the prognosis. The results showed that the concentrations of androgen receptor, hemoglobin and testosterone in 11 androgen-dependent prostate cancer groups were (51.0 ± 14.8)% and (119.0 ± 19.0) g / l, respectively 9.8 ± 7.9) ng / ml. (32.2 ± 118)%, (97.9 ± 18.2) g / l and (4.0 ± 6.4) ng / ml respectively in the 18 androgen-independent prostate cancer groups . Androgen receptor content, hemoglobin, testosterone concentrations compared to the two groups, there was a significant difference. (2) Prostate specific antigen, life status and bone metastasis were (122.8 ± 70.5) ng / ml, 1.5 ± 0.7 and 1.4 ± 0.5 in the androgen-independent prostate cancer groups were (123.3 ± 52.9) ng / ml, 1.8 ± 0.6 and 1.88 ± 0.7, respectively, and there was no statistical difference between the two groups P> 0.05). The above results suggest that: the higher the level of androgen receptor in D_2 prostate cancer tissue, the better the treatment effect. The level of androgen receptor is a good predictor of androgen blockade in patients with advanced prostate cancer.